Table 3 Enrichment of pathways from pre-to-post HTO

Negatively Enriched one year post HTO (higher at baseline)

KEGG

Toll like receptor signaling pathway

-1.72

0.01

0.17

JAK STAT signaling pathway

-1.67

0.02

0.13

Nod like receptor signaling pathway

-1.66

0.03

0.10

Graft vs host disease

-1.59

0.02

0.13

Leishmania infection

-1.57

0.04

0.11

Hematopoietic cell lineage

-1.50

0.06

0.16

Intestinal immune network for IGA production

-1.47

0.09

0.16

T-cell receptor signalling pathway

-1.44

0.11

0.17

Cytokine-cytokine receptor interaction

-1.43

0.05

0.17

Type I diabetes mellitus

-1.42

0.09

0.15

FC epsilon Ri signaling pathway

-1.41

0.10

0.14

Allograft rejection

-1.42

0.13

0.21

Cytosolic DNA sensing pathway

-1.30

0.16

0.21

Asthma

-1.26

0.19

0.23

Rig I-like receptor signaling pathway

-1.26

0.21

0.23

Hallmark

TNF-α signaling via NFκB

-1.62

0.03

0.20

IL-6 JAK STAT3 signaling

-1.61

0.03

0.11

Allograft rejection

-1.50

0.03

0.15

IFNγ response

-1.49

0.09

0.12

Apoptosis

-1.42

0.07

0.14

IL-2 STAT5 signaling

-1.37

0.11

0.14

Positively Enriched one year post HTO (higher after surgery)

KEGG

Pathways in cancer

1.16

0.23

0.86

MAPK signaling pathway

1.07

0.35

0.56

Bladder cancer

0.96

0.5

0.52

Hallmark

Coagulation

1.44

0.09

0.31

Complement

0.97

0.50

1.0

KRAS signaling down

0.88

0.62

0.84

KRAS signaling up

0.60

0.94

0.94